May 13, 2008
Bioniche Updates re: Mycobacterial Cell Wall Technology Platform

May 9, 2008
Bioniche Reports Fiscal 2008 Third Quarter

Check latest
stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.

Business Profile  |  Business Divisions

Bioniche has consistently followed the business model of the fully-integrated pharmaceutical company, maintaining a strategy of internal development of its own products, while acquiring technologies and businesses that are in market areas of interest to Bioniche. The Company has developed the infrastructure and capabilities necessary to conduct and control its scientific discovery, pre-clinical research, manufacturing, clinical studies, regulatory submissions and product registration, leading to commercialization. Bioniche also maintains full control of its products to a late stage of development, before considering entry into distribution partnership agreements rather than conventional licensing arrangements. This approach assures an optimal commercial return to Bioniche and its stakeholders.

Revenues generated by the company’s Animal Health division help to balance risk, drive innovation, develop products and support corporate growth. Bioniche Animal Health is the largest Canadian-owned animal health company, with products marketed though subsidiaries in the United States, Australia and Europe, and a network of distributors worldwide.